11.05.2015 • News

Dow Completes Buyout of ExxonMobil’s Univation Stake

Dow Chemical has acquired ExxonMobil Chemical's share of US technology licensor Univation Technologies for an undisclosed sum. The deal was announced in October 2014.

Previously a 50:50 joint venture of the two US groups, Univation licenses the widely used Unipol polyethylene process and also is a leading manufacturer of catalysts for the process, which permits plant operators to swing between production of linear low density and high density PE grades.

The technology firm also develops and supplies catalysts, including UCAT Conventional, Acclaim Advanced Unimodal, XCAT metallocene and Prodigy bimodal catalysts.

Dow said the purchase of its partner's stake reflects its strategic focus on investing in businesses with strong competitive positions in attractive markets.

Univation Technologies will operate in future as a wholly-owned subsidiary of Dow, led by its president, Steve Stanley, and will continue to be based in Houston, Texas.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read